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Abstract
The glucocorticoid receptor (GR) regulates several physiological functions, including immune function and apoptosis. The
HIV-1 virus accessory protein, viral protein R (Vpr), can modulate the transcriptional response of the GR. Glucocorticoids
(GCs) and Vpr have been reported to induce apoptosis in various cells, including T-cells. We have previously shown that the
injectable contraceptive, medroxyprogesterone acetate (MPA) is a partial to full agonist for the GR, unlike norethisterone
acetate (NET-A). We investigated the functional cross talk between the GR and Vpr in inducing apoptosis in CD4+ T-cells, in
the absence and presence of GCs and these progestins, as well as progesterone. By using flow cytometry, we show that, in
contrast to NET-A and progesterone, the synthetic GR ligand dexamethasone (Dex), cortisol and MPA induce apoptosis in
primary CD4+ T-cells. Furthermore, the C-terminal part of the Vpr peptide, or HIV-1 pseudovirus, together with Dex or MPA
further increased the apoptotic phenotype, unlike NET-A and progesterone. By a combination of Western blotting, PCR and
the use of receptor- selective agonists, we provide evidence that the GR and the estrogen receptor are the only steroid
receptors expressed in peripheral blood mononuclear cells. These results, together with the findings that RU486, a GR
antagonist, prevents Dex-, MPA- and Vpr-mediated apoptosis, provide evidence for the first time that GR agonists or partial
agonists increase apoptosis in primary CD4+ T-cells via the GR. We show that apoptotic induction involves differential
expression of key apoptotic genes by both Vpr and GCs/MPA. This work suggests that contraceptive doses of MPA but not
NET-A or physiological doses of progesterone could potentially accelerate depletion of CD4+ T-cells in a GR-dependent
fashion in HIV-1 positive women, thereby contributing to immunodeficiency. The results imply that choice of progestin used
in contraception may be critical to susceptibility and progression of diseases such as HIV-1.
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Introduction
Globally women account for ,49% of HIV infections [1], with
greater prevalence among young women vulnerable to both
pregnancy and HIV-infection than in men [2]. In Sub-Saharan
Africa, 59% of all those infected are women [3]. There is
substantial evidence from clinical studies that hormonal contra-
ception increases HIV-1 acquisition and transmission in young
women and disease progression, although some of the findings are
controversial, and some studies report no significant effects [4–15].
Of particular interest are the relative effects of the two most
commonly used injectable contraceptives, MPA and norethister-
one enanthate (NET-EN), in HIV-1 infection and AIDS pro-
gression. MPA, administered for contraception as Depo-MPA
(DMPA) or Depo-Provera, is a 150 mg three-monthly intramus-
cular injection that is used by millions of women worldwide and is
widely used in Sub-Saharan Africa and other areas with high
HIV-1 prevalence [6,14–17]. NET-EN is a 200 mg two-monthly
injectable that is used less than MPA, although in countries like
South Africa, its usage varies and is high in some regions [8,17–
19]. Both contraceptives have been shown to be highly effective
and relatively safe regarding most risk factors investigated [20].
However, there is evidence that DMPA but not NET-EN
increases HIV infectivity [5,6,8,10,15,21,22]. Increases in both
HIV-1 and HSV shedding have been reported in women using
contraception [23–25], as well as the presence of more viral
variants and higher viral loads in HIV-1 infected DMPA users
than non-users [7], consistent with an increase in HIV-1
transmission found for DMPA users [5]. DMPA usage has also
been associated with increased acquisition of cervical chlamydial
and gonococcal infections [26]. In addition, while there is evidence
both for and against an increase in disease progression in the
absence of antiretroviral drugs (ARVs) for HIV-1 positive DMPA
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users [7,9,11–13], to our knowledge no information is available for
effects of NET-EN. Whether DMPA or NET-EN affect disease
progression in HIV-1 positive antiretroviral users remains to be
established, although one study suggests no significant change in
CD4+ counts for DMPA users with and without antiretroviral drug
usage [27]. Adjusted hazard ratios (HRs), (reflecting the fold
increased risk relative to no contraception), of between 1.5 and 4.5
fold have been recently reported for DMPA (author’s response in
Gray [4,5,8,10]), while one study reported an HR as high as 10.4
for DMPA [28]. However, establishing indisputable evidence from
such clinical observational studies is extremely difficult due to
multiple confounding factors such as the degree of exposure to
HIV-1, condom usage, HSV-2 exposure as well as varying ages of
women that have been enrolled in these studies [15]. Therefore,
a central question remains as to what extent and via which
mechanisms different synthetic progestins affect HIV-1 pathogen-
esis at contraceptive doses and at various target sites, a question
perhaps best answered by ex vivo studies.
At the cellular level, progestins mediate their effects via
alterations in transcription of specific genes in target cells by
binding to and regulating the activity of steroid receptors, which
are ligand-activated transcription factors [29,30]. Although
progestins are designed to act like the natural ligand progesterone
(P4) via the progesterone receptor (PR), they are likely to exert
very different off target side-effects due to their differential
affinities and activities via other members of the steroid receptor
family of receptors [29–31]. NET-EN is converted to norethister-
one (NET) in the body, while water soluble derivatives of NET-EN
such as NET or norethisterone acetate (NET-A are used orally for
hormone replacement therapy) [27,28]. We have shown that MPA
and NET-A have different affinities for and activities via the
glucocorticoid receptor (GR) [32–34]. MPA binds to the GR with
a relatively high affinity and acts as a full to partial agonist for the
GR, whereas NET-A and P4 bind to the GR with about 100-fold
lower affinity and have little or no activity via the GR. This
differential activity via the GR suggest that MPA and NET may
exert different effects on HIV-1 pathogenesis via the GR, in
particular different effects on immune function, since the GR
regulates transcription of a wide variety of genes involved in
inflammation, immunity, and apoptosis [35,36]. Several different
mechanisms could contribute to the observed effects of DMPA
usage on HIV-1 pathogenesis, including alterations in the
composition of mucosal microflora and thinning of the cervical/
vaginal epithelium. However, the high affinity of MPA for the GR
and the known effects of the GR on immune function suggest that
effects of DMPA on both systemic and local immunity via the GR
may be highly significant.
Although very few studies have investigated this hypothesis,
some do show that MPA affects immune function in vivo in animals
and humans. Two studies in mice provide evidence that MPA
suppresses immune function to increase susceptibility to infections
or reduce defense against disease in mice, at similar doses to those
of women using DMPA [37,38]. Studies in primates have shown
that DMPA reduces systemic immune responses in SIV-infected
macaques [39,40]. MPA used at high doses in cancer therapy is
known to cause significant systemic immunosuppression in
patients [41–44] and a decrease in T-cell numbers and pro-
liferation in breast cancer patients [41,44]. Furthermore, DMPA
as a contraceptive has been shown to compromise cell-mediated
immune status [45] and causes increased recruitment of in-
flammatory cells in cervical vaginal lavages in women [46]. A
recent ex vivo study in primary immune function and cervical cells
from patients showed that MPA, unlike P4, suppresses both innate
and adaptive immune mechanisms at concentrations within the
range of peak serum concentrations found in DMPA users [47,48].
Importantly, the findings from the group of Hel [47] showing
significant repression of IFNl in peripheral blood mononuclear
cells (PBMCs) and lavages from DMPA users but not non-
contraceptive users strongly supports the idea that DMPA
concentrations in vivo are sufficient for immunosuppression. In-
terestingly, P4 is also known to regulate both the innate and
adaptive immune response in the female reproductive tract, other
mucosal tissues as well as systemic immune function in humans.
However, the precise mechanisms and receptors involved in this
regulation are not well understood, but appear to be specific for
different target sites and cell types [6,49,50]. In contrast, very little
is known about the effects of NET-EN/NET/NET-A on immune
function in women.
HIV-1 infection is characterized by rapid and extensive CD4+
T-cell depletion and eventual immunodeficiency. HIV-1-induced
apoptosis appears to play an important role in depletion of CD4+
T-cells, decreasing immune responses to infection and facilitating
viral persistence and increased viral loads and transmission rates
[51]. Furthermore, the loss of CD4+ T-cells correlates with disease
progression and increases in opportunistic infections [52].
Although the exact mechanisms and role of apoptosis during
disease progression remain to be resolved, several HIV-1 proteins
have been implicated in inducing apoptosis in T-cells, including
the 96 amino acid HIV-1 accessory protein viral protein R (Vpr)
[53]. Besides apoptosis, Vpr has been implicated to play a part in
other cellular functions such as cell cycle arrest at G2/M phase
and transport of the pre-initiation complex [53]. Vpr is packaged
within the virus particle where it is thought to be involved in the
early stages of viral replication through transactivation of the HIV-
1 long terminal repeat (LTR) [53]. The clinical observations that
mutations in key Vpr residues are associated with normal capacity
to replicate but loss of cytotoxicity [54] and long-term non-
progressive HIV-1 infections [55], support an important cytotoxic
role for Vpr in HIV-1 infection. Such a cytotoxic role may be
exerted by both virus-associated as well as virus-free Vpr, since
functional Vpr protein has been purified from serum and
cerebrospinal fluid of infected patients [56–58]. Vpr in the plasma
of HIV-1 infected individuals is present at similar concentrations
as the p24 antigen and has the ability to self-penetrate cells
(transduction properties) and to elicit its effects, including
apoptosis, in non-infected bystander cells [56,59]. Mapping
experiments of the Vpr protein indicated that amino acids 1–52
are important for the transduction properties of Vpr, but not for
induction of apoptosis [60]. The C-terminus (amino acids 52–96)
of Vpr, in particular amino acids 71–82 (71-HFRIGCRHSRI-82),
have been shown to be indispensable for apoptotic function [61–
64]. Although Vpr can induce apoptosis via the extrinsic pathway
in neuronal and epithelial cells [65–68], it has been implicated to
act predominately through the intrinsic pathway in a number of
other cell lines and primary cells, including T-cells [69].
Reminiscent of the effects of Vpr on apoptosis, GCs, like
cortisol, (F) acting via the GR, are also potent inducers of apoptosis
in a number of different cells, including T-cells [35]. Several lines
of evidence suggest that Vpr regulates transcription of host and
viral genes via the GR [70]. The mechanism may involve an
interaction of Vpr with the GR to modulate GR transcriptional
activity, as Vpr has been reported to associate with the GR in vitro
and modulate transcription of both host and viral genes [71,72].
This interaction was reported to occur via a signature LXXLL
steroid receptor co-activator motif [73]. Consistent with a role for
the GR in mediating Vpr effects on apoptosis at the transcriptional
level, it has been shown that RU486, a GR antagonist, prevents
Vpr-mediated apoptosis in the Jurkat T-cell line [74].
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Cross talk between Vpr and the GR raises the question as to
how different GR ligands such as MPA would affect GR- and Vpr-
mediated T-cell apoptosis. As both the GR and Vpr have been
implicated to play a role in apoptosis in a number of cell lines and
primary cells, we sought to investigate the possible cross talk
between the GR and Vpr in modulating apoptosis in the presence
of the progestins, MPA and NET-A, and P4 in PMBCs.
Materials and Methods
Ethics Statement
Anonymous buffy packs, otherwise normally discarded, were
obtained from the Western Province Blood Transfusion (WPBT)
services in Pinelands, Cape Town. Written informed consent was
obtained from donors by WPBT and records kept by WPBT. The
Ethics Committee of the University of Cape Town (N05/11/187)
approved the procedure (SFREC_ 04_2010).
Plasmids, Western Blotting and Antibodies
The plasmids used in this study were as follows: pcDNA3-hGR
(GR) plasmid was a gift from Prof. D.W. Ray (Centre for
Molecular Medicine, School of Clinical and Laboratory Sciences,
Faculty of Medical and Human Sciences, University of Manche-
ster, UK). pMT-PR-B (PR) was obtained from Prof. S. Okret
(Karolinka Institute, Sweden). pRS-hMR (MR) expression plasmid
was obtained from Prof. R.M. Evans (University of California,
USA). pSV-hAR (AR) was a kind gift from Frank Claessens
(Catholic University of Leuven, Belguim). pSG5-hER (ER) was
obtained from F. Gannon (EMBL, Germany). The positive
controls for each steroid receptor were generated in COS-1 cells
(ATCC). Briefly, COS-1 cells were seeded at a density of 16105
cells in a 12-well plate. After 24 hrs the cells were transfected with
1 mg of the steroid receptor expression vector using X-treme-
GENE 9 DNA Transfection Reagent (Roche Applied Sciences)
according to the manufacturer’s specifications. The next day
whole cell lysates were prepared using a N-[Tris(hydroxymethyl)-
methyl]-3-aminopropanesulfonic acid (TAPS) buffer (0.1 M
TAPS, pH 9.5) on ice as described by Ronacher et al [34]. PBMC
lysates were also prepared in TAPS buffer from approximately
46106 cells.
Western blotting was performed essentially as previously
described [75]. All antibodies were purchased from Santa Cruz
biotechnology (USA, California). Antibodies included anti-andro-
gen receptor (AR, C-441, sc-7305) anti-estrogen receptor (ER,
MC-20, sc-542), anti-GR (H-300, sc-8992), anti-mineralocorticoid
receptor (MR, C-19, sc-6861), anti-PR (C-20, sc-539) and anti-
glyceraldehyde-3-phosphate dehydrogenase (GAPDH, sc-47724).
Conventional PCR
Conventional PCR was performed using GoTaq DNA poly-
merase (Promega, USA, M3001) with the steroid receptor specific
primers (Table 1) according to the manufacturer’s specifications.
Initial denaturation was for 90 sec at 95uC, while final extension
was for 5 mins at 72uC. The cycling parameters for 35 cycles are
shown in Table 1.
PBMC Isolation, Cell Culture and Test Compounds
Buffy packs were obtained from healthy donors who were
negative for HIV, syphilis and hepatitis B and C. PBMCs were
isolated using Histopaque (H1077 Hybri-MaxTM; Sigma-Aldrich,
South Africa) density centrifugation with Leucosep tubes (Greiner
Bio-One, Germany) according to the manufacturer’s instructions
[76]. PBMCs were cultured in high glucose (4.5 g/ml) Roswell
Park Memorial Institute medium (RPMI) (Gibco, South Africa)
supplemented with 10% (v/v) charcoal-stripped fetal calf serum (c-s
FCS) (Highveld Biological, South Africa), 2 mM L-glutamine
(Sigma-Aldrich, South Africa), 0.1 mg/mL sodium pyruvate
(Sigma-Aldrich, South Africa), 100 IU/ml penicillin and
100 mg/ml streptomycin (Sigma-Aldrich, South Africa) at 37uC
in a water jacket incubator (90% humidity and 5% CO2). Note
that each figure shows the results of experiments using PBMCs
isolated from different donors. Dex ((11b,16a)-9-fluoro-11,17,21-
trihydroxy-16-methylpregna-1,4-diene-3,20-dione), MPA (Me-
droxyprogesterone 17-acetate), NET-A (19-Norethindrone ace-
tate), NET (19-Norethindrone), P4 (progesterone), R5020 (17,21-
dimethyl-19-norpregna-4,9-dien-3,20-dione), Mib (mibolerone),
E2 (estradiol), Ald (Aldosterone) and RU486 (Mifepristone) were
purchased from Sigma-Aldrich, South Africa.
Cell Treatment without Vpr Peptide and Flow
Cytrometric Detection of Apoptosis
Approximately 16106 PBMCs/ml RPMI were seeded into
a 5 mL Becton-Dickinson Falcon tube (352063). Cells were then
treated with either Dex, F, MPA, NET-A, P4 or vehicle control
(EtOH) at the concentrations indicated in the figure legends for
24 hrs at 37uC. After treatment, cells were surface stained and the
apoptotic phenotype detected using the annexin V PE apoptosis
detection kit I according to the manufacturer’s specifications
(Becton-Dickinson-Biosciences; 559763). The following antibodies
Table 1. Primers used for conventional PCR.





95uC (45 sec), 60uC (45 sec), 72uC (45 sec) 209
ER alpha F: 59- TCGACGCCAGGGTGGCAGAG
R: 59-TGGTGCACTGGTTGGTGGCTGG-39
95uC (45 sec), 60uC (45 sec), 72uC (45 sec) 218
GR F: 59-TGCTGTGTTTTGCTCCTGATCTG-39
R: 59-TGTCAGTTGATAAAACCGCTGCC-39
95uC (45 sec), 53uC (45 sec), 72uC (45 sec) 299
MR F: 59-GAGCAGTGGAAGGGCAACAC-39
R: 59-TGGCTGCTCCTCGTGAATCC-39
95uC (45 sec), 60uC (45 sec), 72uC (45 sec) 182
PR A and PR B F: 59-GTGCTCAAGGAGGGCCTGCCG-39
R: 59-TGTGCTGCCCTTCCATTGCCC-39
95uC (45 sec), 60uC (45 sec), 72uC (45 sec) 214
F = Forward; R = Reverse.
doi:10.1371/journal.pone.0062895.t001
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were used to discriminate between cellular populations in PBMCs:
1 mL anti-CD4 fluorescein isothiocyanate (FITC) (Becton-Dick-
inson, 555346), 2 mL anti-CD14 allophycocyanin (APC) (Becton-
Dickinson, 555399) and 1 mL anti-CD3 APC (Becton-Dickinson,
555342) in 50 mL PBS. Samples were acquired using a Becton-
Dickinson FACS Calibur flow cytometer and analysed using Flo Jo
software (Treestar, Inc, Ashland, Ore).
Cell Treatment with Vpr Peptide
The C-terminal Vpr peptide (including amino acids 52–96;
GNTWAGVEAIIRILQQLLFIHFRIGCRHSRIGVTRGR-
RARNGASRS) was a kind gift from Dr Jeffrey Kopp (NIDDK,
National Institutes of Health, Bethesda, USA). Freshly isolated
PBMCs were treated with 5 mM Vpr peptide as previously
described [61]. Briefly, approximately ten million PBMCs were re-
suspended in 1 mL of balanced isotonic glucose-HEPES buffer
(2.4% glucose, 13 mM HEPES, 68 mM NaCl, 1.3 mM KCl,
4 mM Na2HP04 and 0.7 mM KH2PO4, pH 7.2). One million
Table 2. Primers used for real time PCR.





95uC (10 sec), 55uC (10 sec), 72uC (10 sec) 307
Bcl-2 F: 59-TTGTGGCCTTCTTTGAGTTCGGTG-39
R: 59-GTACAGTTCCACAAAGGCATCCCA-39
95uC (10 sec), 60uC (10 sec), 72uC (10 sec) 167
Bim F:59-GAGTGTGACCGAGAAGGTAGACAATTGC-39
R: 59-CCTTCACCTCCGTGATTGCCTTC-39
95uC (10 sec), 55uC (10 sec), 72uC (10 sec) 125
F = Forward; R = Reverse.
doi:10.1371/journal.pone.0062895.t002
Figure 1. The progestin MPA, but not NET-A or P4, induces apoptosis in CD4+ T-cells. Cells were treated with or without 100 nM Dex,
100 nM F, 1 mM MPA, 10 mM NET-A, 1 mM P4 or vehicle control (EtOH) for 24 hrs. Cells were stained with anti-CD4, anti-CD14, annexin V and 7-AAD
using the Apoptosis Detection kit I (BD biosciences). (A) Gating strategy and representative zebra plots of untreated (EtOH), MPA or Dex treated
PBMCs. (B) The histogram shows pooled results from two independent experiments with samples from three donors. Data were acquired on a FACS
calibur system (BD Biosciences) and analyzed using Flo-Jo software (Tree Star Inc., San Carlos, CA, USA). Statistical significance was determined by
one-way ANOVA with Dunnett’s post-test, where *, **, and *** indicate p,0.05, 0.01 and 0.005 respectively. Error bars represent standard deviation.
doi:10.1371/journal.pone.0062895.g001
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cells (100 mL) were treated with 2.5 mg (5 mM) Vpr peptide for
30 min at 37uC. The cells were washed and then cultured in
RPMI. A bovine serum albumin (BSA) trypic digest was prepared
according to a protocol obtained from the Sanford-Burnham
Medical Research Institute (Lo Jolla California, USA [77]) and
served as a control peptide wherever Vpr peptide was not added.
Control peptide was added at a final equivalent concentration as
Vpr, in mass/volume i.e. 25 mg/mL. Cells were treated with the
test compounds as indicated in the figure legends for 24 hrs at
37uC and apoptosis was detected as indicated above. Note that we
found that incubation with this buffer resulted in an increase in
basal apoptosis of the CD4+ T-cell population from about 2.5% to
about 5% (data not shown), which masked apoptotic effects with
MPA alone.
HIV-1 Pseudovirus Generation and Infection
HIV-1 pseudovirus was generated as described by Jochmann
et al [78]. HEK293T cells (obtained from ATCC) were seeded at
a density of 86105 cells/well in a 6-well plate in high glucose (1 g/
ml) phenol red-containing Dulbecco’s Modified Eagles Medium
(DMEM) (Sigma-Aldrich) supplemented with 10% (v/v) fetal calf
serum (FCS) (Highveld Biological, South Africa), 0.1 mg/mL
sodium pyruvate (Sigma, South Africa), 100 IU/ml penicillin and
100 mg/ml streptomycin (Gibco Invitrogen) at 37uC in a water
jacket incubator (90% humidity and 5% CO2). The next day the
cells were washed with PBS and phenol red free DMEM
(supplemented as described above) was added to each well. Cells
were then transfected with 5 mg pSG3.1 (containing the HIV-1
genomic sequences with a mutated envelope (env) gene. (AIDS
Research and Reference Reagent Program; [79]) and pDU15A
(encoding the HIV-1 envelope) [80] using X-tremeGENE 9 DNA
Figure 2. Apoptosis induction by Dex and MPA is most likely mediated primarily through the GR. (A) PBMCs were treated with vehicle
(EtOH), 100 nM MPA, 10 nM Ald, 100 nM E2, 100 nM Mib, 100 nM R5020, 10 mM NET-A or 10 mM NET for 24 hrs at 37uC. Cells were surface stained
with ant-CD3 and anti-CD4 antibodies, and apoptosis was detected using flow cytometry as described in Figure 1. The histogram shows pooled
results from two independent experiments with samples from three donors. Statistical significance was determined by one-way ANOVA with
Dunnett’s post-test, where *** indicates p,0.001. (B) Western analysis of lysates prepared from approximately 46106 PBMCs. Whole cell lysates of
COS-1 cells overexpressing the relevant steroid receptor (+ve) or empty vector (2ve) served as the controls. GAPDH was used as a loading control.
Note that the upper strong band on the MR blot is a COS-1 cell-derived non-specific signal which is absent for PBMCs, while the MR signal is the faint
band just below the non-specific band which is only seen in the positive control. We were unable to obtain a more-specific anti-MR antibody. (C)
Conventional PCR of cDNA prepared from human PBMCs using primers specific for the relevant steroid receptor. The controls were prepared by PCR
amplification of the relative steroid receptor cDNA from plasmid DNA. GAPDH served as a control for mRNA levels. MW: molecular weight; NTC: no
template control. Error bars represent standard deviation.
doi:10.1371/journal.pone.0062895.g002
Figure 3. Dose-dependent apoptosis induction with Dex, MPA,
NET-A and P4 in CD4+ T-cells. PBMCs were treated with vehicle
(EtOH), Dex, MPA, NET-A or P4 at the concentrations indicated for
24 hrs at 37uC. Cells were stained and analysed as described for Figure 1.
The figure shows pooled results from two independent experiments
with samples from three donors. Error bars represent standard
deviation. Statistical trend analysis for each dose response was
performed by the Wilcox rank-sum test, as further extended by Cuzick
[85], and showed a significant trend only for Dex (p,0.001) and MPA
(p= 0.047).
doi:10.1371/journal.pone.0062895.g003
Figure 4. The GR is involved in Vpr-mediated apoptosis in CD4+
T-cells. PBMCs were treated with 1 mM RU486 in the absence or
presence of 5 mM Vpr peptide (amino acids 52–96) for 24 hrs. A tryptic
BSA digest served as a control (bars 1 and 2) wherever Vpr peptide was
not added and was added at an equivalent mass/volume of peptide.
Cells were obtained and stained as described in the methods. The
histogram shows pooled results from two independent experiments
with samples from three donors. Statistical significance was determined
by one-way ANOVA with Dunnett’s post-test or a paired t-test, where *,
**, and *** indicate p,0.05, 0.01 and 0.005 respectively. Error bars
represent standard deviation.
doi:10.1371/journal.pone.0062895.g004
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transfection reagent (Roche, South Africa) according to the
manufacturer’s specifications. Cells were incubated for 3 days at
37uC, the medium passed through a 0.22 mM filter and charcoal-
striped (cs) FCS (Highveld Biological, South Africa) was added to
a final concentration of 40%. The viral stocks were aliquotted and
stored at280uC until use. The titre of the pseudotyped viruses was
determined using the Reed Muench method and expressed as log
TCID50/ml [81]. Prior to infection, PBMCs were activated with
5 mg/ml phytohemagglutinin (PHA) (Sigma Aldrich, South Africa)
and 20 U/ml recombinant human interleukin-2 (rhIL-2) (Roche,-
South Africa) for 3 days as previously described [82]. For
pseudovirus infection, pseudovirus was added to obtain a multi-
plicity of infection (MOI) of 0.00005 and incubated for 3 days
before stimulation and flow cytometric detection of apoptosis. A
standard p24 assay (Aalto Bio Reagents Ltd, Dublin Ireland) was
used to confirm that the cells were infected.
RNA Isolation, cDNA Synthesis and Real Time PCR
Approximately twenty million PBMCs were treated with 5 mM
Vpr or control peptide in 1 mL of balanced isotonic glucose-
HEPES buffer as described previously. Cells were then treated in
the presence or absence of 100 nM Dex, MPA, NET-A or P4 for
24 hrs. The cells were harvested by centrifugation at 3506g and
RNA was extracted using Tri Reagent (Sigma-Aldrich, South
Africa) according to manufacturer’s instructions. RNA was reverse
transcribed with oligo-dT priming, using the Transcriptor High
Fidelity cDNA Synthesis Kit (Roche, South Africa), and an equal
volume of each cDNA synthesis reaction was used as template for
real time PCR, using the Sensimix dT Kit (Quantace, London).
Quantitative PCR was carried out using primers for Bim and Bcl-2
(Table 2). GAPDH was used as a housekeeping gene for
normalization (Table 2; [83]). Initial denaturation and final
extension was as for conventional PCR while the cycling
parameters for 40 cycles are shown in Table 2. Standard curves
were used to determine the efficiency of each primer set, and the
relative expression of the genes of interest in each sample was
calculated according to the Pfaffl mathematical model [84].
Statistical Analysis
All experiments were performed with PBMCs isolated from at
least 3 different donors and at least two independent experiments
were performed. All data was normalized to appropriate controls.
Data were analysed for statistical significance by One-way
ANOVA and appropriate post-tests as indicated in the figure
legends using GraphPad Prism software. *, **, and *** indicate
p,0.05, p,0.01 and p,0.005, respectively. For dose response
analysis, a non-parametric statistical trend test was performed
across the concentration range for each compound, using the
Wilcox rank-sum test, as further extended by Cuzick [85].
Results
An important question is whether doses of DMPA and NET-
EN used for injectable contraception, and physiological con-
centrations of endogenous P4, are sufficient to cause significant
effects on immune function via the GR in vivo. MPA concentra-
tions in the serum of DMPA users are reported to be in the
range of 4.5 to 65 nM a few days after injection of 150 mg and
then to average at about 2.6 nM for about three months
[48,86–89]. NET has been shown to reach a peak plasma
concentration of 50 nM a few days after intramuscular injection
of NET-EN, followed by an average concentration of about
13 nM for about four months [90–92]. The concentration of
endogenous P4 in the serum of premenopausal women varies
from 0.65 nM to about 80 nM between the follicular and luteal
phases, respectively, while reaching about 600 nM during
pregnancy [29]. MPA has a high relative binding affinity for
the GR (Ki of 10.8 nM), similar to that of F (10–20 nM) [93],
whereas NET-A and P4 have lower affinity for the GR (Ki of
270 and 215 nM respectively) [34,94,95]. In order to investigate
effects of P4 and progestins via the GR on apoptosis,
experiments were thus performed at single concentrations
required for near or full saturation of the GR (10–506Kd or
Ki), as well as by dose response analysis using doses spanning
the range of concentrations found in the serum of DMPA and
NET-EN users, or doses spanning physiologically relevant
concentrations for P4. Since NET-EN is not soluble in aqueous
solution, we used the water soluble derivatives NET-A or NET
[29].
GCs and the Progestin MPA, but not NET-A or P4, Induce
Apoptosis in CD4+ T-cells
GCs have been shown to induce apoptosis in several different
cell lines, including CD4+ T-cells [35]. The progestin MPA is
Figure 5. The GR is involved in GC- and Vpr-mediated
apoptosis in CD4+ T-cells. PBMCs were treated with 100 nM Dex
or 1 mM RU486 in the absence or presence of 5 mM Vpr peptide (amino
acids 52–96) for 24 hrs. A tryptic BSA digest added at an equivalent
mass/volume ratio of peptide, served as a control wherever Vpr peptide
was present. Cells were obtained and stained as described in the
methods. The histogram shows pooled results from two independent
experiments with samples from three donors. Statistical significance
was determined by one-way ANOVA with Dunnett’s post-test or a paired
t-test, where *, **, and *** indicate p,0.05, 0.01 and 0.005 respectively.
doi:10.1371/journal.pone.0062895.g005
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a partial to full GR agonist, unlike NET-A and P4 which have
weak to no GR activity [30–33]. We investigated the relative
capability of MPA and NET-A to induce apoptosis in CD4+ T-
cells and CD14+ monocytes, as compared to the endogenous GC
agonist F, the synthetic GR agonist Dex and P4. Briefly, PBMCs
were isolated and treated with 100 nM Dex, 100 nM MPA,
10 mM NET-A, 1 mM P4 or vehicle control (EtOH) for 24 hrs.
Cells were stained with anti-CD4 (T-cells), anti-CD14 (mono-
cytes), 7-aminoactinomycin D (7-AAD), annexin V and the data
were acquired using the Becton Dickinson FACS Calibur. 7-AAD
was included to discriminate between live and dead cells. CD4+ T-
cells and CD14+ monocytes were gated from the total PBMC
population as indicated and the apoptotic cells were detected with
the apoptosis marker annexin V (Figure 1A). As expected Dex and
F induced apoptosis in a statistically significant manner in CD4+
T-cells by about 2-fold and 1.6-fold, respectively, compared to
untreated cells (Figure 1B). Importantly, MPA also statistically
significantly induced apoptosis in these cells (1.5-fold), yet to
a lesser extent than Dex. By contrast, when cells were treated with
NET-A or P4 no increase in apoptosis compared to control, was
detected in CD4+ T-cells (Figure 1B). The apoptotic effect of Dex,
F and MPA was however not observed in CD14+ monocytes (data
not shown) and therefore the following experiments were carried
out in CD4+ T-cells.
MPA Acts Primarily via the GR to Induce Apoptosis in
CD4+ T-cells
Next we sought to provide evidence that the increase in
apoptosis observed with Dex and MPA was mediated via the GR
and did not involve other steroid receptors. Since MPA is a PR
agonist, and a partial agonist for the androgen receptor (AR) and
a partial to full agonist for the GR [29], the possibility that MPA
exerts its apoptotic effects via the PR or AR was investigated
indirectly by using receptor-selective agonists. In order to de-
termine whether other steroid receptors (apart from the GR) could
induce apoptosis, PBMCs were treated with agonists that are
selective for the AR (100 nM Mib), estrogen receptor (ER)
(100 nM E2), mineralocorticoid receptor (MR) (10 nM Ald) and
PR (100 nM R5020), as well as 100 nM Dex, 100 nM MPA,
10 mM NET-A or 10 mM NET for 24 hrs, and apoptosis was
detected using flow cytometry as described previously. The ligands
were used at saturating concentrations for each steroid receptor to
control for the differences in relative binding affinities of each
Figure 6. MPA but not NET-A or P4 increases Vpr-mediated apoptosis in a dose-dependent manner. (A) PBMCs were treated with or
without 5 mM Vpr peptide (amino acids 52–96) and increasing concentrations of MPA, NET-A or P4 for 24 hrs. The graph shows results pooled from
two independent experiments with samples from three donors. (B) PBMCs were treated with 100 nM MPA, 10 mM NET-A, 1 mM P4 or in combination
with 5 mM Vpr peptide (amino acids 52–96) for 24 hrs. Cells were stained and acquired by flow cytometry as described in the materials and methods.
A tryptic BSA digest served as a control wherever Vpr peptide was not added, as for results in figure 4. The histogram shows results pooled from two
independent experiments with samples from three different donors compared to those in figure A. donors. Statistical trend analysis for panel A was
performed by the Wilcox rank-sum test, as further extended by Cuzick [85], and showed a significant trend only for MPA plus Vpr (p = 0.012) and P4
minus Vpr (p = 0.012). Statistical significance in panel B was determined by one-way ANOVA with Dunnett’s post-test or a paired t-test, where *, **,
and *** indicate p,0.05, 0.01 and 0.005 respectively. Error bars represent standard deviation.
doi:10.1371/journal.pone.0062895.g006
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ligand for their respective receptors [33,34,94]. As found earlier,
Dex significantly induced apoptosis by about 2-fold and about 3-
fold in CD3+ and CD4+ T-cells, respectively (Figure 2A). MPA
significantly induced apoptosis by about 1.5-fold compared to
untreated control cells in the CD3+ T-cells and appeared to
increase apoptosis in CD4+ T-cells to a similar extent as observed
before (Figure 1B). In both CD3+ and CD4+ T-cells, the other
steroid receptor-selective agonists did not induce apoptosis in
a statistically significant manner (Figure 2A). Therefore, it is likely
that the effects of MPA on apoptosis are mediated via the GR in
T-cells. In support of these findings, PBMCs expressed GR protein
whereas AR, PR, MR or ER protein expression was not detected
by Western blot analysis (Figure 2B). The ER and MR mRNAs,
but not AR or PR mRNAs, were however detected by PCR,
indicating that ER and MR proteins may be expressed, but at
a level undetectable by Western blot analysis (Figure 2C).
Together with the results presented in Figure 2A, these data show
that if low levels of ER and MR protein are expressed, they have
no effect on apoptosis in CD3+ or CD4+ T-cells (Figure 2A).
Taken together, these results strongly support the finding that the
PR, AR, MR and ER do not induce apoptosis in these cells, and
that MPA acts primarily via the GR to induce apoptosis in
PBMCs. It is noteworthy that NET was included in this
experiment as a control to exclude the possibility that the acetate
form (NET-A) may be less active. However, similarly to NET-A,
NET does not result in apoptosis.
Dex and MPA but not NET-A or P4 Increase Apoptosis in
a Dose-dependent Manner
Having established that both MPA and Dex induce apoptosis in
CD4+ T-cells, we next sought to determine whether this pro-
apoptotic effect was dose-dependent. Statistically significant trends
[85] were observed for Dex (p,0.001) and MPA (p= 0.047), but
not for P4 or NET-A, showing increased apoptosis with increasing
concentrations of ligand, in the absence of Vpr, under these
experimental conditions (Figure 3). Furthermore, apoptotic in-
duction in response to both Dex and MPA was observed, starting
at concentrations as low as 10 nM (Figure 3). The maximal
apoptotic response observed for both Dex and MPA was reached
at 100 nM, and the maximal response for MPA (,1.3-fold) at that
concentration was lower than for Dex (,2.3-fold) (Figure 3). Note
that the fold induction of apoptosis with MPA under these
conditions varies between experiments from about 1.3- to 1.7-fold
(Figures 1,2,3), most likely due to biological variability between
donors. Even though no dose-dependent significant trend for
changes in apoptosis was observed for NET-A or P4, a small
Figure 7. The GR is involved in MPA- and Vpr-mediated apoptosis in CD4+ T-cells. PBMCs were treated with vehicle (EtOH), 100 nM MPA,
1 mM RU486 or 100 nM MPA plus 1 mM RU486, in the absence (A) or presence (B) of 5 mM Vpr peptide for 24 hrs. Cells were stained and acquired by
flow cytometry as indicated in the methods. In A cells were not incubated with balanced isotonic glucose-HEPES buffer while in B, this buffer was
used and a tryptic BSA digest served as a control wherever Vpr peptide was not added, as described in Methods. The histograms show pooled results
from two independent experiments with samples from three donors. Statistical significance was determined by one-way ANOVA with Dunnett’s post-
test or a paired t-test, where *, **, and *** indicate p,0.05, 0.01 and 0.005 respectively. Error bars represent standard deviation.
doi:10.1371/journal.pone.0062895.g007
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response (,1.1-fold) appeared to occur for P4 at 1 mM. These
results are similar to dose-responses observed with these ligands for
transcriptional regulation via the GR, with Dex acting as a full
agonist and MPA as a partial agonist for the GR at concentrations
between 1–100 nM, but with NET-A showing no agonist activity
and P4 very weak to partial agonist activity in some contexts only
at micromolar concentrations [31,34]. Having established that
both Dex and MPA induce apoptosis in the CD4+ T-cells in a dose-
dependent manner, we next sought to determine if Dex and MPA
can enhance Vpr-mediated apoptosis.
Dex Enhances Vpr-mediated Apoptosis in a GR-
dependent Manner
It is well established that Vpr is a potent inducer of apoptosis in
a number of different cell lines and primary cells. Therefore, we
determined whether exogenous C-terminal Vpr peptide could
induce apoptosis via the GR in CD4+ T-cells. As expected, Vpr
peptide significantly induced apoptosis by approximately 1.8-fold
in the CD4+ T-cells (Figure 4). This apoptotic induction was
decreased in the presence of RU486, a potent GR antagonist,
indicating that the GR was involved in Vpr-mediated apoptosis
(Figure 4). We next determined whether Dex could enhance Vpr-
mediated apoptosis through the GR in CD4+ T-cells. Cells were
incubated with Vpr peptide in the absence and presence of Dex.
Vpr and Dex alone induced apoptosis in CD4+ T-cells, although
statistical significance could not be established, most likely due to
the small responses (Figure 5). Furthermore, when cells were
treated with Dex and Vpr in combination, a significant increase in
apoptosis was observed as compared to Vpr or Dex alone. To
establish whether the GR was involved in combined effects of Vpr-
and Dex-mediated apoptosis, cells were treated in the absence and
presence of RU486. RU486 alone had no effect on apoptosis
(Figures 4 and 5). Apoptosis by Dex and Vpr alone was decreased
in the presence of RU486, although statistical significance could
not be established. Importantly, the 3-fold increase in apoptosis
observed when cells were treated with Dex and Vpr in
combination was significantly decreased in the presence of
RU486 (Figure 5). Although RU486 is also a PR and MR
antagonist [29], our data discount a role for these receptors in
apoptosis in these cells (Figure 2). Taken together, the data suggest
that the GR is required for Vpr- and Dex-mediated apoptosis, and
suggests that the GR is required for Vpr enhancement of Dex-
mediated apoptosis.
MPA, but not NET-A or P4, Enhances Vpr-mediated
Apoptosis in a GR-dependent Fashion
Having shown that Dex treatment further increases Vpr-
mediated apoptosis in a GR-dependent fashion, we next sought to
investigate whether MPA, similarly to the full GR-agonist Dex, has
the capability to enhance Vpr-mediated apoptosis. Under the
experimental conditions used in figure 6, we observed statistically
significant [85] trends only for MPA (p= 0.012) in the presence of
Vpr, as well as for P4 in the absence of Vpr (p = 0.005), showing
increased apoptosis with increasing concentrations of ligand
(Figure 6A). Interestingly, a response was observed for MPA in
the presence of Vpr at concentrations as low as 1 nM. A maximal
increase of approximately 6-fold was obtained at a concentration
of 1 mM MPA (Figure 6A). This was in contrast to cells treated in
the absence of Vpr, where MPA appeared to have no dose-
dependent effect on apoptosis (Figure 6A). The lack of apoptotic
activity by MPA alone in these experiments compared to
figures 1,2,3 was likely due to the conditions required to treat
the cells with Vpr or control peptide, which masks the smaller
effects of MPA alone. The dose response results are consistent with
the results in Figure 6B, showing a statistically significant increase
in Vpr-mediated apoptosis with MPA, but not NET-A or P4, using
concentrations of ligands that nearly or fully saturate the GR.
Towards establishing a role for the GR in the MPA response,
further experiments were performed with RU486, in the absence
and presence of Vpr peptide (Figure 7). In the absence of prior
incubation with peptide buffer (see methods), MPA significantly
increased apoptosis compared to untreated CD4+ T-cells
(Figure 7A), as previously shown (Figures 1,2,3). Importantly,
although RU486 alone had no effect on apoptosis, this GR agonist
could reverse MPA-mediated apoptosis in the CD4+ T-cells
(Figure 7A) in a statistically significant manner. Vpr alone
significantly induced apoptosis in CD4+ T-cells, and this response
was decreased in the presence of RU486 (Figure 7A). Vpr and
MPA in combination enhanced apoptosis by about 3-fold in
a statistically significant manner, which was decreased by RU486
(Figure 7B). These results strongly suggest that MPA and Vpr
alone or in combination, enhance apoptosis in CD4+ T-cells via
a mechanism involving the GR. The lack of an effect by the
natural PR ligand P4 or the synthetic progestin NET-A on Vpr-
induced apoptosis is consistent with the requirement for GR
Figure 8. HIV-1-mediated apoptosis is enhanced in the
presence of Dex and MPA. PBMCs were activated in the presence
of PHA and rhIL-2 for 3 days at 37uC as described. Pseudotyped HIV-1
virus or control medium without virus was added to the cells, followed
by incubation for a further 3 days to allow infection. Cells were then
treated with vehicle (EtOH) or 100 nM Dex or MPA for an additional
24 hrs. Acquisition and analysis was carried out as described in the
methods. The histogram shows pooled results from two independent
experiments with samples from three donors. Statistical significance
was determined by one-way ANOVA with Dunnett’s post-test, where *,
**, and *** indicate p,0.05, 0.01 and 0.005 respectively. Error bars
represent standard deviation.
doi:10.1371/journal.pone.0062895.g008
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agonist or strong partial agonist activity of a ligand to modulate
Vpr-mediated apoptosis in CD4+ T-cells.
Dex and MPA Enhance HIV-1-mediated Apoptosis in
CD4+ T-cells
Having shown that Dex and MPA enhance Vpr-mediated
apoptosis using peptide studies, we next determined whether this
effect could be elicited by intact HIV-1 pseudovirus. PBMCs were
first activated with PHA and rhIL-2. Cells were then infected with
pseudotyped HIV-1 virus for 3 days before being treated with the
test compounds as indicated for an additional 24 hrs. The
apoptotic phenotype was detected by flow cytometry as described
above. However, we could not detect CD4+ T-cellsin this assay,
which was most likely owing to decreased expression of the CD4+
receptor following T-cell activation and subsequent infection [96].
Thus, the results are representative of the T-cell population that
was gated from the forward and side scatter plot. The responses
observed from this PBMC population most likely represent the T-
cell population only, because monocytes (which would scatter with
the T-cells) are resistant to ligand- and Vpr-mediated apoptosis
(data not shown; [97]). Consistent with results obtained in
figures 1,2,3 and 5,6,7, stimulation with Dex and MPA resulted
in a statistically significant increase in apoptosis (Figure 8). HIV-1
infection also increased apoptosis, which is consistent with results
obtained with Vpr peptide (Figures 4,5,6,7) and in the literature
[98–100]. Importantly, Dex and MPA stimulation further
enhanced HIV-1 mediated apoptosis. In summary the data
presented here indicate that Dex and MPA have the ability to
increase T-cell apoptosis in the presence of HIV-1.
Dex and Vpr Differentially Regulate Pro- and Anti-
apoptotic Genes
The mechanism of apoptotic induction by the GR and Vpr in
the presence of GR ligands most likely involves the transcriptional
regulation of pro- and anti-apoptotic genes [35,53]. To this end we
set out to identify key genes that could be regulated by both Vpr
and the GR. PBMCs were treated with or without 5 mM Vpr
peptide in the presence or absence of 100 nM Dex, MPA, NET-A
or P4 for 24 hrs (Figure 9 A and B). mRNA levels of potential
target genes were determined by using real time PCR with specific
primers to Bcl-2 or Bim. In the presence of Vpr alone or Vpr in
combination with Dex or MPA, mRNA expression of the anti-
apoptotic factor Bcl-2 was significantly repressed compared to
vehicle-treated cells, although Dex, MPA, NET-A or P4 had no
significant effect in the absence of Vpr (Figure 9A). However, Dex
and MPA alone significantly increased the expression of the pro-
apoptotic factor Bim by approximately 1.7-fold and 1.3-fold,
respectively, whereas Vpr alone had no significant effect
(Figure 9B). Both NET-A and P4 alone or in combination with
Vpr peptide had no effect on Bcl-2 or Bim mRNA levels (Figure 9A
and B). Additionally we found that Vpr and Dex alone or in
combination had no effect on the pro-apoptotic genes Bcl-2-
associated death promoter protein (Bad) and phorbol-12-myr-
istate-13-acetate-induced protein 1 (NOXA) (data not shown).
Figure 9. GC and Vpr differentially regulate key genes involved in apoptosis. PBMCs were treated with or without 5 mM Vpr peptide as
described previously and treated with or without 100 nM Dex, MPA, NET-A or P4 for 24 hrs. After treatment, RNA was extracted, reverse transcribed,
and Bcl-2 (A) or, Bim (B) mRNA expression was measured by real time PCR, normalising to GAPDH expression levels. The histogram shows pooled
results from two independent experiments with samples from three donors. Statistical significance was determined by one-way ANOVA with
Dunnett’s post-test, where *, **, and *** indicate p,0.05, 0.01 and 0.005 respectively. Error bars represent standard deviation.
doi:10.1371/journal.pone.0062895.g009
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Taken together the data suggest that Vpr regulates different genes
involved in the apoptotic pathway as compared to Dex and MPA,
with Dex/MPA up-regulating Bim gene expression and Vpr
decreasing Bcl-2 gene expression. Furthermore, the other steroid
receptor-selective agonists (Ald, E2, Mib and R5020) did not affect
expression of the genes investigated, indicating that the responses
were most likely mediated by the GR (data not shown).
Discussion
In this study we investigated the effects and molecular
mechanisms of the injectable progestin contraceptives, MPA and
NET-A, in CD4+ T-cells on apoptosis, in the absence and
presence of the HIV-1 protein Vpr. It has previously been shown
that GCs and Vpr induce apoptosis in T-cells [35,53], that Vpr
modulates GR function [70] and that MPA, but not NET-A, acts
as a partial agonist for the GR [33,34,95]. We thus hypothesized
that, similarly to GCs, MPA but not NET-A may also increase
apoptosis in CD4+ T-cells, which may be further enhanced in the
presence of Vpr. Consistent with this hypothesis, we show that the
GR agonists Dex and F, as well as MPA, but not NET-A or P4,
induce apoptosis in CD4+ T-cells. The predicted GR ligand
response profile, and the inability of other steroid receptor-
selective agonists to induce apoptosis in these cells, strongly
suggests that the GR is the predominant receptor eliciting this
effect. The relative responses by progestins are consistent with
a lack of involvement of the PR, since MPA, P4 and NET are all
potent PR agonists and hence apoptotic effects via the PR would
be expected to be similar for these ligands, contrary to what is
observed. On the other hand, MPA and NET-A have similar
partial agonist activity via the AR and thus AR-mediated
apoptotic effects via these ligands would be expected to be similar.
Further support for the role of the GR is the finding that only ER,
MR and GR mRNAs were detected in the PBMCs and only the
GR protein but no other steroid receptor proteins were detected
by Western blot analysis. MPA does not bind to and has no
activity via the ER [29], while it binds very weakly but has no
agonist activity on endogenous genes via the MR [101] and hence
the progestins are unlikely to exert any apoptotic effects via these
steroid receptors in PBMCs. Interestingly the AR, ER and MR
have been shown to inhibit apoptosis in skeletal cells, breast cancer
cells, neuronal cells and/or cardiomyocytes, when activated by
their receptor-selective agonists, an effect that is most likely cell-
specific [102,103–105]. Our results showing no detectable PR or
AR, but ER, MR and GR expression in PBMCs are consistent
with the literature [49,106,107]. Furthermore, MPA-induced
apoptosis could be inhibited in the presence of the GR antagonist
RU486. A role for the GR in mediating apoptosis by MPA and
not NET-A or P4 is consistent with the relative binding affinities,
potencies (concentration for half maximal response) and efficacies
(maximal response) for transcriptional regulation by these ligands
via the GR [31–34,95].
As expected, Vpr alone induced apoptosis in CD4+ T-cells,
which was further increased dose-dependently in the presence of
Dex or MPA. Remarkably, MPA appeared to enhance Vpr-
mediated apoptosis at a concentration as low as 1 nM (Figure 6A)
which is lower than the peak and plateau levels observed in the
serum of female patients using DMPA [87]. These findings suggest
that the presence of MPA during HIV-1 infection would further
potentiate the effects of Vpr on apoptosis in T-cells. As
hypothesized due to their weak GR activity, NET-A or P4 did
not induce apoptosis alone or in combination with Vpr. The
increase in apoptosis observed with MPA, Dex or Vpr alone or
Dex and MPA in combination with Vpr was decreased by the GR
antagonist RU486, indicating that the GR is required for these
effects. This is the first report to our knowledge showing that the
GR is required for Vpr-mediated apoptosis in primary T-cells.
The physiological significance of these findings with Vpr require
further investigation. From the literature, it is unclear at what
concentration Vpr occurs in the serum of infected individuals. One
report has detected Vpr in the serum of infected patients at the
same concentrations as circulating viremia [56], whereas another
suggests that Vpr is present at a concentration of 0.7 nM [108].
Higher concentrations of Vpr peptide as used in this study (5 mM)
and by others (1–10 mM) are required to induce apoptosis in vitro
[61,62,99,109]. The intracellular concentrations of Vpr protein
delivered and/or expressed in specific T-cells during chronic
infection are unknown and likely to be much higher than serum
concentrations reflecting Vpr diluted in the total volume of blood
in the body. Thus whether the concentrations of Vpr peptide used
in this study are physiologically relevant is not possible to ascertain
at present. Interestingly, it has been reported that low concentra-
tions of Vpr protect T-cells from apoptosis [110]. These authors
suggested that the levels of Vpr during infection may vary in
a manner that may be crucial to maintaining viral virulence and
increased pathogenesis. Thus, it is possible that the levels of Vpr
vary both in specific cellular environments and during different
stages of disease progression such that at low levels of Vpr,
apoptosis of T-cells does not occur to favour viral replication,
whereas at other stages of the disease, increased Vpr levels may
favour apoptosis and T-cell death.
To investigate whether the results with Vpr peptide are
consistent with a role for Vpr delivered in the context of the
whole virus we treated PBMCs with or without HIV-1
pseudotyped virus in the absence and presence of MPA and
Dex. The results showed that MPA and Dex increase apoptosis
induced by the HIV-1 pseudovirus particles. This result is
consistent with potentiation by GR ligands of apoptosis in the
presence of HIV-1 proteins. However, it does not exclude the
possibility that other proteins besides Vpr are involved in the
response in the context of HIV-1 pseudovirus particles.
Even though the literature suggests that Vpr directly targets the
mitochondria during apoptosis, there is evidence that Vpr is
predominately localized to the nucleus [66,111–113]. It is possible
that a small percentage of Vpr translocates to mitochondria, but
requires the transcription of pro-apoptotic genes in the nucleus to
fully commit to apoptosis. For this reason, Vpr may regulate host
gene expression to induce apoptosis. To determine which genes
are involved in Vpr-mediated apoptosis in the presence of GR
ligands we investigated key genes that have previously been shown
to be regulated by either GCs or Vpr. The anti-apoptotic factor
Bcl-2 was previously identified as a key mediator of apoptosis
because its overexpression in a murine lymphoma cell line
protected cells from GC-induced apoptosis [114]. Bcl-2 has been
shown to be down-regulated by Vpr in a human promonocytic cell
line [97,109]. Key genes that are upregulated by GCs include Bim
in human and murine leukaemia cell lines as well as primary
murine thymocytes [115]. As shown previously [109], the Vpr
peptide down-regulated the anti-apoptotic gene Bcl-2. In contrast,
we show that Dex and MPA, but not NET-A or P4, increased the
expression of the pro-apoptotic genes Bim. Both Vpr and Dex
alone or in combination had no effect on the pro-apoptotic genes
NOXA and Bad (data not shown). Furthermore, no other steroid
receptor-selective agonist enhanced or decreased expression of
Bim or Bcl-2, indicating that the GR was the only steroid receptor
that increased Bim expression (data not shown). Surprisingly Vpr
and Dex did not act in concert to regulate gene expression of any
genes tested. The evidence presented here suggests that the GR
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and Vpr differentially regulate either pro- or anti-apoptotic genes,
most likely resulting in a potent apoptotic response over
a prolonged period of time. In the absence of Vpr, apoptosis is
favoured by GCs or the progestin MPA, by induction of the pro-
apoptotic gene Bim, whereas in the absence of GCs or MPA but
the presence of Vpr, apoptosis is favoured by the repression of the
anti-apoptotic gene Bcl-2. It is likely that the differential regulation
of apoptotic genes by GCs/MPA and Vpr contributes to increased
pathogenicity of the virus and T-cell depletion. We cannot
however rule out the possibility that GCs/MPA and/or Vpr
regulate other genes involved in the apoptosis pathway, or that
Vpr induces apoptosis through direct interaction with the
mitochondrial membrane or that the extrinsic and intrinsic
pathways act together in inducing apoptosis in the CD4+ T-cells.
Taken together, these findings are consistent with a role for
MPA in repressing systemic immune function by increasing
apoptosis in CD4+ T-cells in the absence of HIV-1 infection, and
an increase in this effect in the presence of HIV-1 infection.
Furthermore the findings suggest that this occurs via a mechanism
involving the GC-like properties of MPA, via GR-mediated
changes in transcription of apoptotic genes, which are involved in
the intrinsic apoptotic pathway. The extent to which these
systemic immunosuppressive effects are physiologically relevant
requires further investigation in clinical models, but the dose
response results suggest that the apoptotic effects of MPA could
occur within the peak nanomolar physiological concentration
range measured in serum samples of women on DMPA.
Additionally, the results in Figure 6 suggest that even when the
MPA concentrations drop to about 2.6 nM a few weeks after
injection of DMPA, MPA could potentiate apoptotic effects of Vpr
in HIV-1 infected patients during chronic infection. The apoptotic
effects of MPA in the absence of HIV-1 infection could have a role
in acquisition of the virus owing to compromised immune
responses, whereas the effects of DMPA in the presence of HIV-
1 could have a role in disease progression and depletion of the T-
cell population. These results for MPA are consistent with results
showing a slower cellular immune response rate in DMPA-treated
animals [40] and decreased T-cell numbers in patients treated
with high concentrations of MPA for breast cancer [41].
There is not much information available regarding the effects of
DMPA contraceptive usage on T-cell populations in women.
Synthetic hormones in combined oral preparations, which usually
do not contain MPA, were found not to affect absolute numbers or
percentages of lymphocytes, T-cells and subsets of T-cells
[49,116], consistent with a lack of an effect of contraceptives
other than MPA on T-cell apoptosis. However, our results are
consistent with the findings showing accelerated loss of CD4+ T
cells and death rate in women on DMPA infected with HIV-1
compared to non-contraceptive users [12]. The results in this study
are also consistent with results for women using MPA in HRT,
who exhibited a decrease in total lymphocyte count [117], the
percentage of T-cells [117,118] and the percentage of T-helper
(Th) lymphocytes [117].
Our finding that NET-A does not exhibit these GR-mediated
apoptotic effects like MPA and F, suggests that choice of progestin
contraceptive could significantly affect susceptibility to and
progression of infectious diseases, such as HIV-1 and AIDS. The
finding that P4 at concentrations less than 1 mM does not induce
apoptosis in T-cells suggests that P4 concentrations in the luteal
phase of the menstrual cycle [29] are unlikely to affect immune
function via apoptosis of T-cells. These findings highlight the fact
that not all progestins are the same [29,31,33,119] and that choice
of progestin in hormonal therapy needs to be carefully considered.
The choice of progestin for contraception may be particularly
important for young women of child bearing age in the developing
world in high risk areas for HIV-1 infection, where MPA usage as
an injectable contraceptive is high [120].
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